CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Fresenius And Wuxi Biologics Enter Exclusive Development Agreement To Expand Biosimilars Pipeline

By Reuters News

Nov 2 (Reuters) -

  • FRESENIUS AND WUXI BIOLOGICS ENTER EXCLUSIVE DEVELOPMENT AGREEMENT TO EXPAND BIOSIMILARS PIPELINE

  • FRESENIUS WILL DETERMINE LONG-TERM MANUFACTURING STRATEGY FOR EACH CANDIDATE, WITH OPTIONALITY TO LEVERAGE MABXIENCE NETWORK, WHOLLY OWNED SINCE OCTOBER 2026

  • AGREEMENT GIVES FRESENIUS FULL STRATEGIC FLEXIBILITY TO SELECT AND ADVANCE BIOSIMILAR CANDIDATES TO DEVELOP, AGAINST ITS ESTABLISHED SELECTION CRITERIA, WHILE RETAINING FULL COMMERCIALIZATION ECONOMICS OF PRODUCTS UNDER AGREEMENT

  • EXCLUSIVE OPTION RIGHTS FOR UP TO 37 POTENTIAL FIRST-TO-MARKET BIOSIMILAR CANDIDATES TO SIGNIFICANTLY EXPAND FRESENIUS' PORTFOLIO

  • NEXT-GENERATION PORTFOLIO SPANS 13 THERAPEUTIC AREAS AND MULTIPLE BIOLOGIC TECHNOLOGIES, INCLUDING MONOCLONAL AND BISPECIFIC ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND FUSION PROTEINS

  • PROVIDES ACCESS TO INCREASE PORTFOLIO FROM 29 MARKETED AND PIPELINE MOLECULES TODAY TO UP TO 66 MOLECULES

  • IT PROVIDES ACCESS TO A SCALABLE PATHWAY TO INCREASE PORTFOLIO , ADDRESSING MORE THAN EUR 370 BILLION IN ORIGINATOR LIST-PRICE-BASED-SALES

Further company coverage: FREG.DE

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.